Paper Details

  1. Home
  2. Paper Details

Carrier-Free Nanoassembly of Curcumin-Erlotinib Conjugate for Cancer Targeted Therapy.

Author: ChengChen, HuXiangxiang, ShiShanshan, SuiBinglin, WangMingming, XuPeisheng

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

A carrier-free nanoparticle, EPC nanoassembly, was developed based on the self-assembly of the curcumin-erlotinib conjugate. This nanoassembly exhibited more potent cell killing, better antimigration, and anti-invasion effects for BxPC-3 pancreatic cancer cells than the combination of free curcumin and erlotinib. EPC nanoassembly effectively accumulated in the tumor tissue of a xenograft pancreatic tumor mouse model, effectively reduced the growth of pancreatic tumors, and extended the median survival time of the tumor-bearing mice from 22 to 68 days. No systemic toxicity was detected in the mice receiving EPC treatment.
Paper Details　
Original Abstract of the Article :
Anticancer drug-loaded nanoparticles have been explored extensively to decrease side effects while improving their therapeutic efficacy. However, due to the low drug loading content, premature drug release, nonstandardized carrier structure, and difficulty in predicting the fate of the carrier, only...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/32893507

データ提供：米国国立医学図書館（NLM）

Curcumin-Erlotinib Conjugate Nanoassembly: A Powerful Tool for Targeted Cancer Therapy

This research takes us into the cutting-edge world of nanotechnology, where we explore the potential of a novel carrier-free nanoassembly of curcumin-erlotinib conjugate (EPC) for targeted cancer therapy. Much like a camel navigating a complex desert labyrinth, this nanoassembly offers a promising approach to delivering cancer drugs directly to tumor cells, minimizing side effects and maximizing therapeutic efficacy. The authors developed this innovative nanoassembly, demonstrating its effectiveness in killing cancer cells, inhibiting migration, and reducing tumor growth in a preclinical model. This research offers a potential breakthrough in the fight against cancer.

EPC Nanoassembly Shows Promise in Targeted Cancer Therapy

The study found that the EPC nanoassembly exhibited significantly better anti-cancer activity than the combination of free curcumin and erlotinib. This nanoassembly effectively accumulated in tumor tissue, reducing tumor growth and extending the survival of mice with pancreatic cancer. This research provides a glimmer of hope for individuals seeking effective and safe cancer treatments.

Navigating the Desert of Cancer Research

Cancer research is a constant quest for innovative and effective treatments. This research highlights the potential of nanotechnology in delivering targeted therapies, minimizing side effects and improving patient outcomes. Just as a skilled navigator utilizes a compass to guide their journey, researchers are continually seeking new tools and strategies to navigate the complexities of cancer treatment.

Dr. Camel's Conclusion

This study demonstrates the potential of EPC nanoassembly as a powerful tool for targeted cancer therapy. Its ability to effectively kill cancer cells, inhibit migration, and reduce tumor growth offers a promising new approach to treating cancer.

Date :
  1. Date Completed 2021-05-14
  2. Date Revised 2023-11-12
Further Info :

Pubmed ID

32893507

DOI: Digital Object Identifier

NIHMS1639346

Related Literature

Article Analysis
・Side Effects of erlotinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.